Checkmate Pharmaceuticals Inc represents a commitment to revolutionizing cancer treatment through innovative immunotherapies. The company's corporate philosophy revolves around harnessing the power of the immune system to eliminate tumors and enhance patients' overall well-being. Checkmate Pharmaceuticals is driven by a patient-centric approach, emphasizing the development of groundbreaking therapies that prioritize efficacy, safety, and durability. By relentlessly pursuing scientific advancements and collaborating with leading experts, Checkmate Pharmaceuticals aims to make a significant impact in the fight against cancer. Their transformative vision and dedication to empowering patients solidify Checkmate Pharmaceuticals Inc as an industry leader in oncology research and development.

Checkmate Pharmaceuticals Inc is primarily present in the United States. As a biotechnology company, it focuses on developing innovative immunotherapies to combat cancer. With its headquarters located in Cambridge, Massachusetts, Checkmate Pharmaceuticals Inc operates nationwide to advance its research and clinical trials. By leveraging its expertise in the field, the company aims to provide effective treatment options for patients battling various types of cancers.

Checkmate Pharmaceuticals Inc has achieved several significant milestones. Firstly, the company successfully completed a Phase 1 clinical trial for its lead product candidate, CMP-001, which demonstrated promising results in patients with advanced melanoma. In addition, Checkmate Pharmaceuticals Inc received Fast Track designation from the U.S. FDA for CMP-001, which expedites the development and review process. Furthermore, the company initiated a Phase 2 clinical trial to evaluate CMP-001 in combination with a PD-1 inhibitor for various solid tumor indications. These achievements highlight the company's dedication to advancing innovative immunotherapies and its potential for addressing unmet needs in oncology.

Checkmate Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing advanced cancer immunotherapies. Founded in 2015, the company is dedicated to pioneering the delivery of innovative treatments using its proprietary technology, the CpG STAT3 inhibitor. Checkmate aims to combat a wide range of cancers by activating and enhancing the patient's immune system response. By targeting the STAT3 pathway, Checkmate Pharmaceuticals Inc aims to overcome the tumor's immune evasion mechanisms. With a mission to improve cancer outcomes, Checkmate Pharmaceuticals Inc continues to drive research and development in the field of cancer immunotherapy.

The main competitors of Checkmate Pharmaceuticals Inc in the market are companies such as Bristol Myers Squibb, Merck & Co., and AstraZeneca.

Checkmate Pharmaceuticals Inc is primarily active in the biotechnology industry.

Checkmate Pharmaceuticals Inc is a biopharmaceutical company specializing in the development of immunotherapies to combat cancer. The company focuses on utilizing its proprietary platform to activate the innate immune system and stimulate T cells to fight against tumors. Checkmate Pharmaceuticals aims to develop innovative treatments that can enhance the body's immune response and provide better survival outcomes for cancer patients. With a core emphasis on immunotherapies, Checkmate Pharmaceuticals Inc is dedicated to advancing novel treatment options in the fight against cancer.

Коефициентът на цена спрямо печалбата (КЦП) на Checkmate Pharmaceuticals е -2,36.

Коефициентът на цена към оборот (KUV) на Checkmate Pharmaceuticals е 4,85.

AlleAktien качественият резултат за Checkmate Pharmaceuticals е 2/10.

очаквана Checkmate Pharmaceuticals оборотът е 46,77 млн. USD.

очаквана Checkmate Pharmaceuticals печалба е -95,99 млн. USD.

Checkmate Pharmaceuticals Inc is a research-driven biotechnology company focused on developing novel immunotherapies with the potential to revolutionize the treatment of multiple types of cancer. The company is headquartered in Cambridge, Massachusetts and was founded in 2015. It is a leader in the development of immunotherapies based on checkpoint inhibitors, the Program for the Identification of Drug Targets (PACT), and other modern approaches to combating cancer. Checkmate Pharmaceuticals is at the forefront of developing immunotherapies targeting checkpoint inhibitors. This technology aims to activate the body's immune system to fight cancer. The company has also developed the PACT program, which aims to identify new immunotherapy targets and develop actionable immune epitopes. Additionally, the company is focused on state-of-the-art technologies such as CRISPR/Cas to develop artificial immune cells or genetically modified anti-cancer cells. The company has developed and conducted multiple clinical programs in the field of immunotherapy and cancer treatment. The company's leading therapy is currently CMP-001, an immunotherapy for the treatment of melanoma that works based on toll-like receptors. This therapy has shown promising results in early clinical investigations and has the potential to become the first approved immunotherapeutic drug for the treatment of melanoma. Checkmate Pharmaceuticals has a variety of patents and exclusive technologies to develop innovative immunotherapies and cancer treatments. The company also collaborates closely with leading academic institutions and research institutes to integrate new insights and technologies and expand its development and innovation capabilities. The business model of Checkmate Pharmaceuticals is based on innovation in the development of new immunotherapies and cancer treatments. The company works closely with medical professionals to successfully test its therapies and document medical achievements. Checkmate's profits come from selling its patented and exclusive immunotherapies and cancer treatments to patients and the medical community. In summary, Checkmate Pharmaceuticals is a research-driven biotechnology company focused on developing novel immunotherapies and cancer treatments. The company's business model is based on innovation in the development of exclusive therapies and patents in the field of cancer treatment. The company works closely with medical professionals to test its therapies and expand its presence in the market. Checkmate Pharmaceuticals has the potential to develop the first approved immunotherapeutic drug for the treatment of melanoma, paving the way for further development of immunotherapies in cancer treatment.

Checkmate Pharmaceuticals разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Checkmate Pharmaceuticals в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Checkmate Pharmaceuticals е US1628181083.

WKN на Checkmate Pharmaceuticals е A2QAMD.

Тикерът на Checkmate Pharmaceuticals е CMPI.

През последните 12 месеца Checkmate Pharmaceuticals изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Checkmate Pharmaceuticals да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Checkmate Pharmaceuticals в момента е .

Checkmate Pharmaceuticals изплаща дивидент на тримесечие. Той се разпределя в месеците .

Checkmate Pharmaceuticals платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Checkmate Pharmaceuticals се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Checkmate Pharmaceuticals на 2.10.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 2.10.2024 г..

Последното дивидентно плащане беше извършено на 2.10.2024 г..

През година 2023 Checkmate Pharmaceuticals изплати 0 USD под формата на дивиденти.

Дивидентите от Checkmate Pharmaceuticals се изплащат в USD.